Company research
AIM ImmunoTech Inc.
CIK 946644Updated Sep 27, 2026
SecurityAIM · NYSE_AMERICAN · equity
Name history
AIM ImmunoTech Inc. · through Sep 18, 2026HEMISPHERX BIOPHARMA INC · through Aug 26, 2019
AIM price & chart
Loading TradingView…
AMEX:AIM on TradingView ↗About the company
We are focused on pancreatic cancer because testing results to date — primarily conducted in the Netherlands — have been very promising. The Netherlands study generated statistically significant data indicating that Ampligen extended survival well beyond the Standard of Care (“SOC”), when compared to well-matched historical controls. These data support the proposition that Ampligen, when administered to either patients with locally advanced or metastatic pancreatic cancer after systemic chemotherapy, showed a statistically significant increase in survival rate. In October 2021, we and our Contract Research Organization, Amarex, submitted an IND application to the FDA for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. In December 2021, the FDA responded with a Clinical Hold on the proposed study. We submitted our response to the FDA in February 2022. In March 2022, we received notification from the FDA that the Clinical Hold was released and cleared, meaning that we are now able to proceed with the study specifically to treat locally advanced pancreatic cancer patients. In August 2022, we received IRB approval of the…
In the news
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules ↗
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 1.02, 3.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 5,782,000Source | 8,608,000Source | 19,381,000Source | 40,488,000Source |
| Property, Plant and Equipment, NetUSD | 71,000Source | 108,000Source | 127,000Source | 195,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,985,000Source | 1,701,000Source | 5,439,000Source | 27,053,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 7,000Source | — | 1,184,000Source | — |
| Assets, CurrentUSD | 3,295,000Source | 4,176,000Source | 14,556,000Source | 36,321,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 241,000Source | 199,000Source | 302,000Source | 455,000Source |
| Operating Lease, Right-of-Use AssetUSD | 378,000Source | 618,000Source | 697,000Source | 829,000Source |
| Other Assets, NoncurrentUSD | 377,000Source | 1,112,000Source | 1,688,000Source | 1,202,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 15,565,000Source | 9,930,000Source | 9,147,000Source | — |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 696,000Source |
| Common Stock, Value, IssuedUSD | 3,000Source | 66,000Source | 49,000Source | 48,000Source |
| Additional Paid in CapitalUSD | 431,000,000Source | 425,440,000Source | 419,004,000Source | 418,270,000Source |
| Retained Earnings (Accumulated Deficit)USD | -440,786,000Source | -426,828,000Source | -409,508,000Source | -380,546,000Source |
| Stockholders' Equity Attributable to ParentUSD | -9,783,000Source | -1,322,000Source | 10,234,000Source | 38,468,000Source |
| Liabilities and EquityUSD | 5,782,000Source | 8,608,000Source | 19,381,000Source | 40,488,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 6,224,000Source | 9,535,000Source | 8,652,000Source | 1,361,000Source |
| Operating Lease, Liability, CurrentUSD | 250,000Source | 239,000Source | 223,000Source | 178,000Source |
| Accounts Payable, CurrentUSD | 1,630,000Source | 6,383,000Source | 6,443,000Source | 377,000Source |
| Operating Lease, Liability, NoncurrentUSD | 170,000Source | 395,000Source | 495,000Source | 659,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 795,000Source | 606,000Source | 1,986,000Source | 806,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 2,807,000Source | — | — |
| Long-term Debt, Current MaturitiesUSD | 3,549,000Source | 2,307,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 927,000Source | — | — | — |
| Short-term InvestmentsUSD | — | — | 7,631,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 60,000Source | 686,000Source | 243,000Source | 954,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | -1,184,000Source | -492,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | -1,712,000Source | -60,000Source | 6,066,000Source | 179,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -10,957,000Source | -14,888,000Source | -21,267,000Source | -16,108,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 1,853,000Source | 4,706,000Source | -832,000Source | 10,988,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 18,000Source | — | 86,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,388,000Source | 6,444,000Source | 485,000Source | 80,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,284,000Source | -3,738,000Source | -21,614,000Source | -5,040,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 247,000Source | — | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | — | 302,000Source | — | — |
| Amortization of Debt Issuance CostsUSD | 552,000Source | 301,000Source | — | — |
| Amortization of Intangible AssetsUSD | 173,000Source | 209,000Source | 199,000Source | 218,000Source |
| DepreciationUSD | 37,000Source | 37,000Source | 39,000Source | 38,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 200,000Source | -1,679,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | -176,000Source | -751,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | 376,000Source | -928,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 18,000Source | — |
| Gain (Loss) on InvestmentsUSD | 17,000Source | -93,000Source | 200,000Source | -1,679,000Source |
| Gain (Loss) on Sale of DerivativesUSD | -4,411,000Source | -458,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 18,000Source | 3,000Source |
| General and Administrative ExpenseUSD | 7,700,000Source | 13,714,000Source | 21,137,000Source | 13,074,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 1,138,000Source | — | — | — |
| Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 17,000Source | -93,000Source | 200,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | -56,000Source | -93,000Source | — | — |
| Marketable Securities, Unrealized Gain (Loss)USD | 73,000Source | -570,000Source | — | -928,000Source |
| Net Income (Loss) Attributable to ParentUSD | -13,958,000Source | -17,320,000Source | -28,962,000Source | -19,445,000Source |
| Other Nonoperating Income (Expense)USD | 3,183,000Source | 5,192,000Source | 1,069,000Source | 629,000Source |
| Payments to Acquire InvestmentsUSD | — | 361,000Source | 1,593,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 88,000Source | 170,000Source | 202,000Source | 141,000Source |
| Operating Income (Loss)USD | -11,664,000Source | -19,772,000Source | -31,916,000Source | -19,923,000Source |
| Other Nonoperating Income (Expense)USD | 3,183,000Source | 5,192,000Source | 1,069,000Source | 629,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -13,958,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -13,958,000Source | -17,320,000Source | -28,962,000Source | -19,445,000Source |
| Earnings Per Share, BasicUSD per share | -8.62Source | -0.31Source | -0.6Source | -0.4Source |
| Earnings Per Share, DilutedUSD per share | -8.62Source | -0.31Source | -0.6Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,618,617Source | 56,016,870Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,618,617Source | 56,016,870Source | 48,585,404Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 173,000Source | 209,000Source | 199,000Source | 218,000Source |
| Costs and ExpensesUSD | 11,752,000Source | 19,942,000Source | 32,118,000Source | 20,064,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | -176,000Source | -751,000Source |
| Gain (Loss) on InvestmentsUSD | 17,000Source | -93,000Source | 200,000Source | -1,679,000Source |
| General and Administrative ExpenseUSD | 7,700,000Source | 13,714,000Source | 21,137,000Source | 13,074,000Source |
| Interest ExpenseUSD | 812,000Source | 585,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | -56,000Source | -93,000Source | — | — |
| Research and Development ExpenseUSD | 3,924,000Source | 6,197,000Source | 10,939,000Source | 6,990,000Source |
Offerings
Registration 333-296871
Registration 333-296588
Registration 333-292085
- Gross proceeds
- 12000000.0
- Net proceeds
- 11040000.0
- Deal price
- 1000.0
- Shares
- 12000
- Offering price
- $1,000,
- Ticker
- AIM
Registration 333-284443
Filing attachments
ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biodefense Is Force Protection: Ready Today, Prepared for Tomorrow A decorated combat aviator and biotech CEO advocates preparing for novel viral threats before the next crisis. By Thomas K. Equels America treats biodefense too much like a public health backstop and not enough like military force protection. That must change. As a former Army helicopter gunship pilot who flew more than 300 combat missions, an instructor pilot and a TRADOC projec…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Dosing in Metastatic Pancreatic Cancer Phase 2 Trial, Positioning Company for Key Clinical Milestones Through Early 2027 Pancreatic Cancer Remains Strategic Priority as AIM Advances Tow…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency OCALA, Fla., June 15, 2026 / AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today announced that it has received written notice from the NYSE American that AIM has regained compliance with NYSE…
Read attachment ↗ex4-1.htm · 8-K · 2026-06-11
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAIL…
Read attachment ↗ex4-2.htm · 8-K · 2026-06-11
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAIL…
Read attachment ↗ex4-3.htm · 8-K · 2026-06-11
EX-4.3 4 ex4-3.htm EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THEY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAIL…
Read attachment ↗